Impact of endoscopic ultrasound on the management and outcome of pancreatic carcinoma

Abstract

More patients (62%) were diagnosed with pancreatic carcinoma when using endoscopic ultrasound and 75% fewer required operations for diagnosis. The 3-month improvement in median survival is probably multifactorial but most likely represents lead bias because of the greater sensitivity of endoscopic ultrasound for pancreatic carcinoma. Using endoscopic ultrasound with endoscopic ultrasound-guided fine needle aspiration in patients with pancreatic carcinoma significantly affects their management and outcomes.

Rapid on-site cytopathological examination (ROSE) performed by endosonagraphers and its improvement in the diagnosis of pancreatic solid lesions

“…Consequently, pathological examination is often required to establish a definitive diagnosis [10][11][12][13] .…”

Yield of endoscopic ultrasound-guided fine-needle aspiration biopsy in patients with suspected pancreatic carcinoma

“…A tissue diagnosis is often required to direct therapy in the face of uncertain diagnosis or if the patient is not a surgical candidate either due to advanced disease or comorbidities. [1][2][3] Endoscopic ultrasound (EUS) is a relatively new technology that employs endoscopy and highfrequency ultrasound (US). EUS involves imaging of the pancreatic head and the uncinate from the duodenum and imaging of the body and tail from the stomach.…”

Endoscopic Ultrasound for Solid and Cystic Neoplasms of the Pancreas

“…The needle is then moved back and forth several times (5-10 passes) with varying degrees of negative pressure to collect cells or small tissue samples that are then deposited on cytology slides for immediate fixation and staining 60 . EUS-FNA of primary pancreatic malignancies is able to provide a definitive diagnosis in 80-93% of cases 8,54,57,[61][62][63] . The ability to have a cytopathologist on site who can provide immediate feedback on the quality and adequacy of the specimens obtained by FNA is extremely important for the accurate diagnosis 62,63 .…”

“…EUS-FNA of primary pancreatic malignancies is able to provide a definitive diagnosis in 80-93% of cases 8,54,57,[61][62][63] . The ability to have a cytopathologist on site who can provide immediate feedback on the quality and adequacy of the specimens obtained by FNA is extremely important for the accurate diagnosis 62,63 . Choosing what part of a pancreatic mass to aspirate is something of an art and comes with experience.…”